BeiGene Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)


You May Also Like

True Life Chiropractic Assists Military Service Members with Accessible Chiropractic

ANCHORAGE, Alaska, March 19, 2017 (GLOBE NEWSWIRE) -- Military services member, veterans, and their ...

CytomX Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), ...